Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Llusern Scientific Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is concentrated under 1 distinct examiner and 1 distinct art unit, indicating a focused prosecution footprint at this stage. The concentration of work suggests that the portfolio's current interactions with the patent office are centralized.
The busiest examiner for the company is ZOU, NIANXIANG, who is responsible for 1 busiest examiner pending office action. Because the total pending office actions and the busiest examiner's workload both equal 1, this individual handles the company's current patent examination pipeline. Practitioners should note that the outcome of this specific interaction will define the company's immediate success in the Biotechnology & Pharmaceuticals sector.
With 1 distinct art unit involved, the company's legal strategy does not currently need to account for varying examination standards across different USPTO divisions. The concentration of 1 pending office action under ZOU, NIANXIANG allows for a focus on the specific preferences and historical tendencies of this examiner. This streamlined profile suggests a narrow but critical phase of prosecution for the current portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558490 | NUCLEIC ACID DETECTION | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558490 | NUCLEIC ACID DETECTION | ZOU, NIANXIANG | 1671 | §102 | Non-Final OA | — | Pending | Nov 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLlusern Scientific Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nianxiang Zou has the most, with 1 of Llusern Scientific Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
